Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Awad

Showing results (791-800 of 839) with videos related to

Pageof 84
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2023
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung CancerRohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi, et al.
The New England Journal of Medicine|April 11, 2022
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung CancerPatrick M Forde, Jonathan Spicer, Shun Lu, et al.
Future Oncology (London, England)|February 23, 2023
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancerPatrick M Forde, Jonathan Spicer, Shun Lu, et al.
JTO Clinical and Research Reports|October 14, 2024
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or CemiplimabBiagio Ricciuti, Arielle Elkrief, Jessica Lin, et al.
The New England Journal of Medicine|May 15, 2024
Perioperative Nivolumab in Resectable Lung CancerTina Cascone, Mark M Awad, Jonathan D Spicer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2025
Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective StudyLingzhi Hong, Alessandro Di Federico, Bolun Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2019
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel DiseaseHamzah Abu-Sbeih, David M Faleck, Biagio Ricciuti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2022
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinomaS Scalera, B Ricciuti, M Mazzotta, et al.
JCI Insight|October 5, 2016
Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypesPatrick H Lizotte, Elena V Ivanova, Mark M Awad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2023
Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung CancerBiagio Ricciuti, Arielle Elkrief, Joao Alessi, et al.
Pageof 84

Showing results (791-800 of 839) with videos related to

Sort By:
Pageof 84
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2023
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung CancerRohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi, et al.
The New England Journal of Medicine|April 11, 2022
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung CancerPatrick M Forde, Jonathan Spicer, Shun Lu, et al.
Future Oncology (London, England)|February 23, 2023
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancerPatrick M Forde, Jonathan Spicer, Shun Lu, et al.
JTO Clinical and Research Reports|October 14, 2024
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or CemiplimabBiagio Ricciuti, Arielle Elkrief, Jessica Lin, et al.
The New England Journal of Medicine|May 15, 2024
Perioperative Nivolumab in Resectable Lung CancerTina Cascone, Mark M Awad, Jonathan D Spicer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2025
Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective StudyLingzhi Hong, Alessandro Di Federico, Bolun Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2019
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel DiseaseHamzah Abu-Sbeih, David M Faleck, Biagio Ricciuti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2022
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinomaS Scalera, B Ricciuti, M Mazzotta, et al.
JCI Insight|October 5, 2016
Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypesPatrick H Lizotte, Elena V Ivanova, Mark M Awad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2023
Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung CancerBiagio Ricciuti, Arielle Elkrief, Joao Alessi, et al.
Pageof 84